Cholera
Methodology & AI Transparency ⓘ
Cholera Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cholera is a bacterial infection that causes diarrhea .
- 2 Real-world patient consensus: Diagnostic registry B00.8: Cholera is managed within Infections & Antivirals.
- 3 Typical cash cost range: Differential triage of Cholera (B00.8) utilizes antimicrobial stewardship (narrow-spectrum in Cholera (B00.8: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for Cholera (B00.8): Complete Blood Count in Cholera (B00.8: (WBC & Differential)) & C-Reactive Protein / in Cholera (B00.8: Procalcitonin) (Resolution to baseline (B00.8)).
Ask our AI Specialists anything about Cholera
What Is Cholera?
Cholera is a bacterial infection that causes diarrhea . The cholera bacterium is usually found in water or food that has been contaminated by feces (poop). Cholera is rare in the US. You may get it if you travel to parts of the world with poor water and sewage treatment. Outbreaks can also happen after disasters. The disease is not likely to spread directly from person to person. Cholera infections are often mild. Some people don't have any symptoms. If you do get symptoms, they usually start 2 to 3 days after infection. The most common symptom is watery diarrhea. In some cases, the infection can be severe, causing lots of watery diarrhea, vomiting, and leg cramps.
Pathophysiology, Underlying Causes & Clinical Presentation
Cholera (B00.8) alters infections & antivirals homeostasis through tissue neutrophil/lymphocyte recruitment [Cholera B00.8]; Cross-referenced with NIH MeSH (Cholera), clinical remission targets C-Reactive Protein / in Cholera (B00.8: Procalcitonin) within Resolution to baseline (B00.8).
Common Symptoms & Clinical Signs
- • Use only bottled or purified water for drinking, washing dishes, making ice cubes, and brushing your teeth
- • If you do use tap water, boil it or use iodine tablets
- • Presentation of Cholera (B00.8): sore throat, productive in Cholera (B00.8: cough, sinus/ear pain,)
- • Secondary Cholera clinical sign: painful vesicular rash in Cholera (B00.8: in a dermatomal)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cholera Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B00.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Cholera (B00.8: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B00.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Cholera (B00.8: Procalcitonin) | Resolution to baseline (B00.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Cholera (B00.8: Culture & Sensitivity) | Pathogen clearance / negative test (B00.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cholera
Treatment selection for Cholera depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cholera)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A gold-standard blind, randomised phase III clinical trial to evaluate safety,: What a 1,800-Participant Study Found The findings indicate that BBV131 demonstrates non-inferior immunogenicity and comparable safety to Shanchol™ in healthy Indian adults and children, supporting its potential as an effective OCV. Vaccine • 2025-05-10 • Phase III Randomized Trial | N = 1,800 | 96/100 | PMID 40174256 ↗ |
| New Insights on Immunogenicity and safety of a quadrivalent high-dose inactivated influenza: What a 1,528-Participant Study Found IIV4-HD provided superior immunogenicity versus IIV4-SD and was well tolerated in adults aged ≥60 y. Human vaccines & immunotherapeutics • 2021-12-02 • Phase III Randomized Trial | N = 1,528 | 96/100 | PMID 34714720 ↗ |
| New Insights on Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283: What a 10,000-Participant Study Found The estimated hazard ratios per 10-fold increase in Day 29 nAbs against D614G, BA.4/BA.5, and XBB.1.5 were 0.70 (95% confidence interval [CI]: 0.48-1.02; p = .064), 0.49 (95% CI: 0.41-0.58; p p < .001), respectively. Human vaccines & immunotherapeutics • 2026-12-15 • Phase III Randomized Trial | N = 10,000 | 90/100 | PMID 42220116 ↗ |
Cholera Patient Community & “People Like Me” Threads
Filter Cholera community threads and patient logs by age, biological sex, dosage, and treatment duration.